Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

University of Alberta

$27,000.00

Jonathan Gerber Master's Canada Research Scholarhsip

EF 2025-26

Résumé
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that causes memory loss and cognitive decline. In Canada, AD affects ~7% of the population over the age of 65, and its prevalence doubles every 5 years thereafter. AD is associated with neuronal loss, intracellular clumping of tau protein, and extracellular deposits of B-amyloid (AB) peptides. The basal forebrain cholinergic neurons, which provide major input to the hippocampus and cortex, the areas involved in learning and memory processing, are most severely affected in AD. The levels of acetylcholine (ACh) and its synthetic enzyme are markedly decreased in the cortex and hippocampus of AD brains. Various drugs that prevent the breakdown of ACh have been widely used to treat symptoms in AD patients. Developing a therapeutic strategy to protect the forebrain cholinergic neurons may lead to an effective treatment for AD patients. Poly(D,L-lactide-co-glycolic) (PLGA) nanoparticles are a family of FDA-approved biodegradable polymers used to deliver ~20 drugs in a variety of human diseases. In its native form, PLGA has been shown to protect against AB toxicity, decrease disease pathology in neurons from AD patients, and reduce cognitive deficits and pathology in the 5xFAD mouse model of AD. However, no evidence is available on whether PLGA influences the cholinergic system in AD brains. This project will address the following two objectives: 1) To determine if chronic administration of PLGA nanoparticles restores the integrity of the basal forebrain cholinergic neurons in 5xFAD mice by measuring various cholinergic markers. 2) To assess if PLGA treatment lessens cognitive deficits in 5xFAD mice. Overall, this project will address the therapeutic benefits of native PLGA in the treatment of AD pathology.
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
572627
Name
Gerber Jonathan
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Jonathan Gerber Master's Canada Research Scholarhsip
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
5xfad Mouse Model; Acetylcholine; Alzheimer'S Disease; Amyloid Precursor Protein; Beta-Amyloid; Cholinergic System; Cognition; Native Plga Nanoparticles; Neurodegeneration; Therapeutic Treatment
Abstract
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that causes memory loss and cognitive decline. In Canada, AD affects ~7% of the population over the age of 65, and its prevalence doubles every 5 years thereafter. AD is associated with neuronal loss, intracellular clumping of tau protein, and extracellular deposits of B-amyloid (AB) peptides. The basal forebrain cholinergic neurons, which provide major input to the hippocampus and cortex, the areas involved in learning and memory processing, are most severely affected in AD. The levels of acetylcholine (ACh) and its synthetic enzyme are markedly decreased in the cortex and hippocampus of AD brains. Various drugs that prevent the breakdown of ACh have been widely used to treat symptoms in AD patients. Developing a therapeutic strategy to protect the forebrain cholinergic neurons may lead to an effective treatment for AD patients. Poly(D,L-lactide-co-glycolic) (PLGA) nanoparticles are a family of FDA-approved biodegradable polymers used to deliver ~20 drugs in a variety of human diseases. In its native form, PLGA has been shown to protect against AB toxicity, decrease disease pathology in neurons from AD patients, and reduce cognitive deficits and pathology in the 5xFAD mouse model of AD. However, no evidence is available on whether PLGA influences the cholinergic system in AD brains. This project will address the following two objectives: 1) To determine if chronic administration of PLGA nanoparticles restores the integrity of the basal forebrain cholinergic neurons in 5xFAD mice by measuring various cholinergic markers. 2) To assess if PLGA treatment lessens cognitive deficits in 5xFAD mice. Overall, this project will address the therapeutic benefits of native PLGA in the treatment of AD pathology.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Gerber, Jonathan
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~